Category Archives: Drugs

Competition Commission of India pulls up Roche for anti-competitive practices

By Jyotsna Singh, Scroll | April 27, 2017 In a landmark order, the commission has initiated an investigation into the multinational pharmaceutical company’s activities. The Competition Commission of India has initiated an investigation into Swiss pharmaceutical giant Roche for unfair … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , | Leave a comment

Pharma Companies Should Sell Medicines Under Generic Names! Generic Prescription by Doctors is NOT Enough

Press Release: April 26, 2017 All India Drug Action Network Demands Substantive Measures   The proposal, as announced by the Prime Minister, to make generic prescription writing mandatory for doctors, would be a useless counterproductive step as a standalone measure. This … Continue reading

Posted in Drug prices, Generics, Uncategorized | Leave a comment

CCI to investigate Swiss drugmaker Roche over breast cancer biosimilar

By Divya Rajagopal, The Economic Times | April 26, 2017 MUMBAI: The Competition Commission of India (CCI) will investigate Swiss drugmaker Roche over alleged attempts to block competitors from selling breast cancer drug Trastuzumab. The investigation has to be completed … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Tagged , , , , | Leave a comment

Indian competition commission issues a path breaking order on abuse of dominant position in pharmaceuticals

Rules Roche’s practices prima facie appear to be aimed at blocking affordable biosimilar trastuzumab – a cancer drug – in India In July 2016, Mylan Pharmaceuticals and Biocon Limited approached the Competition Commission of India regarding Roche’s anti-competitive conduct to … Continue reading

Posted in Anti competition, Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer | Tagged , , , , , | Leave a comment

Compulsory licensing in Colombia: Leaked documents show aggressive lobbying by Novartis

Novartis has threatened Colombia with international investment arbitration to avoid the issuance of a compulsory license.* The Swiss pharma giant is also turning to Colombian courts in an attempt to kill the price reduction imposed by the authorities over its … Continue reading

Posted in BITS, Drug prices, Drugs, ISDS, Pricing | Leave a comment

The high price of Big Pharma greed

By Leena Menghaney, The Hindu | March 4, 2017 In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, … Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Tagged , , | Leave a comment

MSF calls on Japan and South Korea to drop the harmful RCEP measures

Kobe, Japan/New Delhi 22 February 2017 As 16countries negotiating the Regional Comprehensive Economic Partnership (RCEP)agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, international medical humanitarian organisation Médecins Sans Frontières (MSF) is appealing tothe Japanese and South … Continue reading

Posted in Data Exclusivity, Drug prices, Generics, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment